Harbour BioMed wins China IND filing acceptance for HBM7004
Bottom line
Harbour BioMed said China’s National Medical Products Administration has accepted its investigational new drug application for HBM7004, a B7-H4xCD3 bispecific antibody being developed for advanced solid tumors. The June 10 announcement follows U.S. FDA clearance of the same program on May 8, which allowed a first-in-human Phase 1 trial to move forward in the U.S. Harbour BioMed says HBM7004 was built on its HBICE platform and, in preclinical studies, showed B7-H4-dependent intratumoral T-cell activation, antitumor activity in multiple animal models, in vivo stability, and reduced systemic toxicity. (prnewswire.com)
Why it matters: For veterinary professionals tracking oncology innovation, this is still a human drug-development story, but it’s relevant because bispecific antibodies and T-cell engagers remain a closely watched class for solid tumors, where efficacy and safety have both been hard to balance. HBM7004’s design aims to localize immune activation around a tumor-associated target, and Harbour BioMed has highlighted a potential combination path with its B7-H4x4-1BB program, HBM7008. More broadly, reviews of the field note that CD3-directed bispecifics in solid tumors face persistent challenges, including cytokine-related toxicity and the immunosuppressive tumor microenvironment, so early regulatory progress doesn’t answer the bigger clinical questions yet. (prnewswire.com)
What to watch: The next step is whether Harbour BioMed starts enrolling the U.S. Phase 1 study and whether China’s IND acceptance progresses to trial initiation, with early safety data likely to be the first real inflection point. (prnewswire.com)
Harbour BioMed has added a second regulatory milestone for HBM7004, announcing on June 10 that China’s NMPA accepted its IND application for the candidate in advanced solid tumors. The move comes just over a month after the company disclosed U.S. FDA IND clearance on May 8, giving the B7-H4xCD3 bispecific antibody a clearer path into first-in-human clinical testing across two major markets. (prnewswire.com)
HBM7004 has been in Harbour BioMed’s preclinical pipeline for some time. In the company’s 2024 interim report, Harbour BioMed described the asset as a novel B7-H4xCD3 bispecific antibody discovered through its Harbour Mice and HBICE platforms, and said the program had advanced to the near-IND stage during 2024. The company has framed the asset as part of a broader strategy to build immune cell engagers that try to improve on the efficacy-safety tradeoffs that have limited some earlier immuno-oncology approaches. (harbourbiomed.com)
The company’s latest disclosure was narrow but important: NMPA acceptance means the filing has been received for review, not that the product is approved. Harbour BioMed said HBM7004 is intended for advanced solid tumors and is designed to drive B7-H4-dependent T-cell activation within tumors. In both the China and U.S. announcements, the company cited preclinical evidence of antitumor activity in multiple animal models, in vivo stability, and reduced systemic toxicity. The U.S. filing goes a step further on trial design, stating that the first-in-human Phase 1 study is expected to assess safety, tolerability, pharmacokinetics, and antitumor activity in people with advanced solid tumors. (prnewswire.com)
There’s also a combination angle. Harbour BioMed has said HBM7004 showed synergy in preclinical models when paired with HBM7008, a B7-H4x4-1BB bispecific antibody, at a low effector-to-target cell ratio. A 2022 SITC abstract reported that the HBM7008-HBM7004 combination could enhance T-cell activation, reduce T-cell apoptosis, and increase T-cell division, supporting the company’s suggestion that the pair could widen the therapeutic window. That remains preclinical, but it helps explain why Harbour BioMed is emphasizing platform versatility rather than a single standalone asset. (prnewswire.com)
Industry context matters here. Bispecific antibodies have become a major oncology development focus, but solid tumors remain more difficult than hematologic cancers. Reviews in Nature Reviews Clinical Oncology and other journals describe a central tension for CD3-directed bispecifics: developers need enough immune activation to generate tumor killing, while avoiding cytokine release, off-tumor effects, and other systemic toxicities. Separate reviews of 4-1BB agonism also note that the target has long been scientifically attractive, but prior programs struggled with liver toxicity or inadequate efficacy, which is why tumor-localized or conditional activation strategies keep drawing attention. (nature.com)
B7-H4 is part of that story because it has emerged as a tumor-associated target in several solid malignancies. A recent Clinical Cancer Research review described B7-H4 as broadly expressed across cancers, with especially high expression in tumors arising from female reproductive organs, and highlighted growing interest in therapeutic strategies directed at the target. That doesn’t validate HBM7004 specifically, but it does support Harbour BioMed’s rationale for pursuing a B7-H4-based engager in solid tumors. (aacrjournals.org)
Why it matters: For veterinary professionals, this is mainly a signal about where comparative oncology and next-generation immunotherapy are heading. Companion-animal oncology still has limited access to advanced bispecific platforms, but human oncology pipelines often foreshadow the modalities, safety questions, and biomarker strategies that may later influence translational research and specialty practice. The bigger takeaway is that developers are still trying to solve the same core problem seen across species: how to activate immune cells strongly enough to affect solid tumors without creating unacceptable toxicity. HBM7004 is one more example of that push toward more conditional, target-dependent immune engagement. (prnewswire.com)
What to watch: Near term, watch for trial-start details in the U.S., any update on whether the China filing advances from acceptance to active clinical testing, and eventually the first safety readouts. For a CD3-based bispecific in solid tumors, those early data will likely matter more than the filing milestone itself. (prnewswire.com)